Pemigatinib is a type of inhibitor that specifically goes after FGFR2 gene fusions in people with cholangiocarcinoma. The medicine has three different strengths – 4.5 mg, 9 mg, or 13.5 mg tablets. The suggested dose is 13.5 mg once a day, but you take it non-stop for 14 days in a month-long cycle.
You can get Pemigatinib in bottles of 14 pills each. This treatment stops FGFR messaging to help deal with the illness. People who have FGFR2 gene fusions can try this medicine.
Reviews
There are no reviews yet.